Unichem Laboratories Ltd Stock Falls to 52-Week Low of Rs.324.6

Stock Performance and Market Context

On 2 Mar 2026, Unichem Laboratories Ltd (Stock ID: 270205) opened sharply lower with a gap down of -6.51%, closing the day at its intraday low of Rs.324.6. This represents a decline of -3.86% on the day and extends the stock’s losing streak to three consecutive sessions, during which it has fallen by -6.5%. The stock’s performance today notably lagged the Pharmaceuticals & Biotechnology sector by approximately 3%.

Unichem Laboratories is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish momentum. In contrast, the broader Sensex index, despite opening sharply down by 2,743.46 points, recovered by 1,672.71 points to trade at 80,216.44, down -1.32% for the day. The Sensex remains below its 50-day moving average, although the 50DMA is positioned above the 200DMA, indicating mixed medium-term market signals.

Long-Term and Recent Returns

Over the past year, Unichem Laboratories has delivered a total return of -44.97%, significantly underperforming the Sensex’s positive return of 9.59% over the same period. The stock’s 52-week high was Rs.727.95, highlighting the extent of the recent decline. The underperformance extends beyond the last year, with the stock lagging the BSE500 index over the last three years, one year, and three months, underscoring persistent challenges in maintaining shareholder value.

Financial Metrics and Profitability Concerns

Unichem Laboratories’ financial profile reveals several areas of concern that have contributed to the stock’s decline. The company’s Debt to EBITDA ratio stands at a high 4.87 times, indicating a relatively low capacity to service its debt obligations. This elevated leverage level is a key factor in the current market sentiment.

Profitability metrics also reflect subdued performance. The average Return on Equity (ROE) is a modest 1.44%, signalling limited profitability generated per unit of shareholders’ funds. Furthermore, the company’s net sales have grown at an annualised rate of 11.95% over the past five years, which is considered moderate within the Pharmaceuticals & Biotechnology sector.

Recent quarterly results have added to the cautious outlook. The Profit Before Tax excluding other income (PBT LESS OI) for the quarter ending December 2025 was Rs.6.11 crores, representing a sharp decline of -77.2% compared to the previous four-quarter average. The Profit After Tax (PAT) for the latest six months stood at Rs.62.50 crores, down by -24.22%, while interest expenses increased by 30.50% to Rs.15.66 crores over the same period. These figures highlight pressures on earnings and rising financing costs.

Valuation and Operational Highlights

Despite the challenges, Unichem Laboratories exhibits some positive operational indicators. The company’s operating profit has grown at an impressive annual rate of 148.09%, reflecting underlying business growth. Additionally, the Return on Capital Employed (ROCE) is 4.9%, and the enterprise value to capital employed ratio is 1, suggesting an attractive valuation relative to the capital invested.

The stock currently trades at a discount compared to its peers’ average historical valuations. Over the past year, while the stock price has declined by -44.97%, profits have increased by 29.9%, resulting in a Price/Earnings to Growth (PEG) ratio of 0.8. This indicates that the market valuation may not fully reflect the company’s profit growth trajectory.

Shareholding and Market Grade

Promoters remain the majority shareholders of Unichem Laboratories Ltd, maintaining significant control over the company’s strategic direction. The company’s Mojo Score is 31.0, with a current Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 16 Feb 2026. The Market Cap Grade is 3, reflecting its mid-tier market capitalisation status within the Pharmaceuticals & Biotechnology sector.

Summary of Key Factors Behind the 52-Week Low

The stock’s fall to Rs.324.6, its lowest level in 52 weeks, is the result of a combination of factors. These include a sustained decline in share price over the past year, underperformance relative to the Sensex and sector indices, and financial metrics that point to elevated leverage and modest profitability. The recent quarterly earnings decline and rising interest expenses have further weighed on investor sentiment.

While the company’s operating profit growth and valuation metrics offer some counterbalance, the overall market response has been cautious, reflected in the stock’s trading below all major moving averages and its current Mojo Grade of Sell. The stock’s performance remains a key indicator of the challenges faced by Unichem Laboratories in navigating its financial and market environment.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →